Cancer Discovery | BBO-11818: A Non-covalent Pan-KRAS Inhibitor Targeting Both ON and OFF States of Mutant KRAS

This study provides a critical molecular tool for developing KRAS-targeted strategies to overcome resistance mechanisms, particularly inspiring the design of combination therapies and construction of resistance models for KRAS-mutant solid tumors.

 

Literature Overview

The article titled 'Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants,' published in Cancer Discovery, systematically explores the discovery, mechanism of action, and antitumor activity of the novel non-covalent pan-KRAS inhibitor BBO-11818. Using structure-based drug design, the research team developed a highly selective small-molecule inhibitor capable of targeting multiple oncogenic KRAS mutants (e.g., KRASG12D, KRASG12V) in both GTP-bound (ON) and GDP-bound (OFF) states. The compound demonstrates excellent oral bioavailability and pharmacokinetic properties, overcoming previous limitations of inhibitors targeting only specific mutations or nucleotide states. The study comprehensively validated its potent signal suppression and tumor regression in cellular and animal models, and explored synergistic effects with immune checkpoint inhibitors, anti-EGFR antibodies, and RAS:PI3Kα disruptors, laying a solid foundation for clinical development.

Background Knowledge

KRAS mutations are highly prevalent in lung, colorectal, and pancreatic cancers and serve as core oncogenic drivers of tumor progression. Although KRASG12C inhibitors have been approved, effective targeted therapies against more common KRASG12D and KRASG12V mutations remain lacking, representing a major unmet clinical need. Traditional targeting strategies have been hindered by the lack of classical druggable pockets on the KRAS protein surface and its picomolar affinity for GTP, making competitive inhibition extremely challenging. In recent years, while the Switch-II allosteric pocket has been identified, most inhibitors only act on the OFF state of KRAS, whereas the ON state continuously activates downstream signaling in tumors and is a root cause of resistance. Additionally, single-agent targeting often leads to bypass activation, such as feedback upregulation of EGFR or compensatory PI3K pathway activity. Therefore, there is an urgent need for pan-inhibitors that simultaneously target both ON and OFF states of KRAS and cover multiple mutations to achieve deep and durable pathway suppression. This study addresses this unmet need by designing and validating BBO-11818—a broad-spectrum, potent, and orally active non-covalent KRAS inhibitor—offering a new paradigm for overcoming the 'undruggable' nature of KRAS.

 

 

Research Methods and Experiments

The study employed a structure-based drug design (SBDD) strategy, optimizing the C4 substituent of the covalent KRASG12C inhibitor BBO-8520 to enhance binding affinity for multiple KRAS mutants and improve oral bioavailability. Surface plasmon resonance (SPR) and HTRF protein-protein interaction (PPI) assays were used to systematically evaluate the binding kinetics and functional inhibition of BBO-11818 against different nucleotide states (GDP/GppNHp) and mutant subtypes (KRASG12D, KRASG12V, etc.). X-ray crystallography resolved the complex structures of BBO-11818 with KRASG12D in both ON and OFF states, revealing its binding to the Switch-II/helix 3 pocket and induction of conformational inactivation of Switch-I. 31P-NMR experiments further confirmed that BBO-11818 shifts the KRAS conformational equilibrium toward the inactive state (state 1). In cellular models, cancer cell lines harboring various KRAS mutations and genetically edited MEF cells were used to assess inhibition of MAPK signaling and cell viability via pERK detection and 3D spheroid proliferation assays. In animal models, pharmacological efficacy was evaluated in multiple KRAS-driven CDX (e.g., HPAC, GP2d) and PDX (LU2049) models, including monotherapy and combination regimens (e.g., anti–PD-1, cetuximab), with tumor growth and survival monitored.

Key Conclusions and Perspectives

• BBO-11818 binds to both ON and OFF states of multiple KRAS mutants (e.g., KRASG12D, KRASG12V) with low nanomolar affinity. SPR data show a KD value <0.003 nM for GDP-KRASG12D, significantly outperforming the lead compound BBO-8520, indicating its broad-spectrum inhibition potential and providing a template for developing inhibitors covering a wider spectrum of KRAS mutations.
• Crystal structures reveal that BBO-11818 binds to the Switch-II/helix 3 pocket of KRAS, inducing conformational changes in Switch-I that prevent effector protein (e.g., RAF1) binding. This mechanism is highly conserved in both ON and OFF states, supporting its dual inhibitory function and providing an atomic-level blueprint for designing conformation-selective KRAS inhibitors.
• BBO-11818 strongly suppresses pERK signaling and cell proliferation (EC50 < 30 nM) in multiple KRASG12D and KRASG12V mutant cell lines, and remains effective in KRAS-amplified cells, indicating its ability to overcome signal hyperactivation due to gene amplification and suggesting potential applications in tumors with high KRAS pathway burden.
• In pancreatic, colorectal, and NSCLC models driven by KRASG12D and KRASG12V mutations, BBO-11818 monotherapy induces significant tumor regression (TGI >80%), and combinations with anti–PD-1, cetuximab, or BBO-10203 produce synergistic antitumor effects, supporting its potential as a backbone agent for combination therapies, especially in contexts of EGFR feedback activation or PI3K pathway compensation.
• BBO-11818 shows reduced activity against the KRASQ61R mutant in MEF cells, suggesting its efficacy may be limited to specific mutation types, pointing toward future research on resistance mechanisms and the development of next-generation inhibitors.

Research Significance and Prospects

This study marks a significant breakthrough in the development of pan-KRAS inhibitors. As the first potent non-covalent inhibitor targeting the ON state of KRAS, BBO-11818 provides a new tool to overcome the limitations of current KRAS-targeted therapies restricted to the OFF state, potentially addressing resistance caused by GTP-KRAS accumulation. Its oral bioavailability and favorable pharmacokinetic properties support convenient clinical use, and it has already entered Phase I trials (NCT06917079), offering new hope for patients with various KRAS-mutant solid tumors. From a drug development perspective, the success of this molecule validates the feasibility of non-covalent pan-KRAS inhibition, encouraging further development of broad-spectrum inhibitors targeting the Switch-II pocket. Moreover, its synergistic effects with multiple targeted therapies provide preclinical rationale for constructing combination regimens that achieve deep responses (e.g., KRAS+EGFR, KRAS+immunotherapy), advancing the optimization of precision combination strategies.

 

 

Conclusion

The BBO-11818 reported in this study represents a major advance in KRAS-targeted therapy. As a potent, selective, and orally bioavailable non-covalent pan-KRAS inhibitor, it effectively targets multiple oncogenic KRAS mutants in both ON and OFF states, overcoming limitations of previous inhibitors. It demonstrates strong tumor-suppressive activity in various KRAS-mutant solid tumor models and exhibits synergistic effects with immunotherapy, anti-EGFR, and PI3K pathway inhibitors, highlighting its potential as a cornerstone of combination therapies. From bench to bedside, BBO-11818 not only offers new therapeutic hope for patients with KRASG12D and KRASG12V mutations but also establishes pan-KRAS inhibition as a viable strategy. Its entry into clinical trials marks a pivotal transition from 'undruggable' to 'druggable,' profoundly impacting the future care of KRAS-driven cancers such as pancreatic, colorectal, and non-small cell lung cancers, and advancing personalized precision medicine to deeper levels.

 

Carlos Stahlhut, Anna E Maciag, Kyle A Sullivan, Frank McCormick, and Pedro J Beltran. Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants. Cancer Discovery.